Summary
Schering-Plough Corporation (MRK) filed this 8-K on October 21, 2004, to report its financial results for the third quarter of 2004. The filing includes a press release detailing these results and supplemental financial data, both attached as exhibits. This report provides investors with an update on the company's operational and financial performance during the specified quarter. The company also included a significant disclosure regarding forward-looking statements and cautionary factors that could materially affect future results. Investors should pay close attention to these risks, which encompass competitive pressures, pricing challenges, regulatory uncertainties (including the impact of the Medicare Prescription Drug Act of 2003), product development risks, potential efficacy or safety concerns, patent disputes, and manufacturing compliance issues. The disclosure emphasizes that actual results may differ significantly from projections due to these factors.
Key Highlights
- 1Schering-Plough reported its Third Quarter 2004 financial results via an 8-K filing.
- 2The filing includes a press release (Exhibit 99.1) detailing the quarterly financial performance.
- 3Supplemental financial data for the quarter is also provided as an exhibit (Exhibit 99.2).
- 4The report contains extensive cautionary language regarding forward-looking statements.
- 5Key risks highlighted include competitive pressures, pricing challenges, and regulatory impacts (e.g., Medicare Modernization Act).
- 6Product development, manufacturing compliance, and patent disputes are identified as significant risk factors.
- 7The company's major products (CLARITIN, CLARINEX, INTRON A, etc.) are noted as contributing materially to revenues, with associated risks.
- 8The potential impact of new products like ZETIA and VYTORIN, and the launch of VYTORIN on ZETIA sales, is mentioned.